Evidence that brain tissue volumes are associated with HVA reactivity to metabolic stress in schizophrenia

Schizophrenia Research

Volumn 86, Issue 1-3, 2006, Pages 45-53

  Marcelis, Machteld ^a   Suckling, John ^b   Hofman, Paul ^c   Woodruff, Peter ^d   Bullmore, Ed ^b   van Os, Jim ^a,e  

^a Department of Psychiatry and Psychology   (Netherlands)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Brain alteration; Dopamine; Homovanillic acid; Magnetic resonance imaging; Metabolic stress; Schizophrenia

Indexed keywords

GLUCOPRIVIC 2 DEOXYGLUCOSE; GLUCOSE DERIVATIVE; HOMOVANILLIC ACID; PLACEBO; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; AUTOMATION; BRAIN ATROPHY; BRAIN METABOLISM; BRAIN SIZE; BRAIN TISSUE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAY MATTER; HUMAN; MALE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; REGRESSION ANALYSIS; SCHIZOPHRENIA; SCHOOL CHILD; STRESS; WHITE MATTER;

ADOLESCENT; ADULT; DEOXYGLUCOSE; FEMALE; HOMOVANILLIC ACID; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SCHIZOPHRENIA; TIME FACTORS;

EID: 33747400567     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.05.001     Document Type: Article

References (46)

1. 123I]iodobenzamide. Biol. Psychiatry 55 (2004) 1001-1006
2. Adler C.M., Elman I., Weisenfeld N., Kestler L., Pickar D., and Breier A. Effects of acute metabolic stress on striatal dopamine release in healthy volunteers. Neuropsychopharmacology 22 5 (2000) 545-550
3. Amin F., Davidson M., and Davis K.L. Homovanillic acid measurement in clinical research: a review of methodology. Schizophr. Bull. 18 1 (1992) 123-148
4. Breier A. A.E. Bennett award paper. Experimental approaches to human stress research: assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients. Biol. Psychiatry 26 5 (1989) 438-462
5. Breier A., Buchanan R.W., Elkashef A., Munson R.C., Kirkpatrick B., and Gellad F. Brain morphology and schizophrenia. A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch. Gen. Psychiatry 49 (1992) 921-926
6. Breier A., Davis O., Buchanan R., Listwak S.J., Holmes C., Pickar D., and Goldstein D.S. Effects of alprazolam on pituitary-adrenal and catecholaminergic responses to metabolic stress in humans. Biol. Psychiatry 32 10 (1992) 880-890
7. Breier A., Crane A.M., Kennedy C., and Sokoloff L. The effects of pharmacologic doses of 2-deoxy-d-glucose on local cerebral blood flow in the awake, unrestrained rat. Brain Res. 618 2 (1993) 277-282
8. Breier A., Davis O.R., Buchanan R.W., Moricle L.A., and Munson R.C. Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume. Arch. Gen. Psychiatry 50 7 (1993) 541-550
9. Burns J., Job D., Bastin M.E., Whalley H., Macgillivray T., Johnstone E.C., and Lawrie S.M. Structural disconnectivity in schizophrenia: a diffusion tensor magnetic resonance imaging study. Br. J. Psychiatry 182 (2003) 439-443
10. Davis KL., Kahn R.S., Ko G., and Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148 (1991) 1474-1486
11. Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., Fearon P., McGuire P., Mallet R.M., Jones P.B., Leff J., and Murray R.M. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 30 4 (2005) 765-774
12. Deutch A.Y., Clark W.A., and Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of the mesolimbic dopamine neurons to stress. Brain Res. 521 1-2 (1990) 311-315
13. Elman I., Sokoloff L., Adler C.M., Weisenfeld N., and Breier A. The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers. Brain Res. 815 2 (1999) 243-249
14. Friston K.J., and Frith C.D. Schizophrenia: a disconnection syndrome?. Clin. Neurosci. 3 2 (1995) 89-97
15. Glenthoj B.Y. The brain dopaminergic system. Pharmacological, behavioural and electrophysiological studies. Dan. Med. Bull. 42 (1995) 1-21
16. Goldstein H. Multilevel Models in Educational and Social Research (1987), Griffin, London
17. Hegarty A.A., and Vogel W.H. The effect of acute and chronic diazepam treatment on stress-induced changes in cortical dopamine in the rat. Pharmacol. Biochem. Behav. 52 4 (1995) 771-778
18. Heinz A., Romero B., Gallinat J., Juckel G., and Weinberger D.R. Molecular brain imaging and the neurobiology and genetics of schizophrenia. Pharmacopsychiatry 36 Suppl 3 (2003) S152-S157
19. Hubl D., Koenig T., Strik W., Federspiel A., Kreis R., Boesch C., Maier S.E., Schroth G., Lovblad K., and Dierks T. Pathways that make voices: white matter changes in auditory hallucinations. Arch. Gen. Psychiatry 61 7 (2004) 658-668
20. Hulshoff Pol H.E., Schnack H.G., Mandl R.C.W., Cahn W., Collins D.L., Evans A.C., and Kahn R.S. Focal white matter density changes in schizophrenia: reduced inter-hemispheric connectivity. Neuroimage 21 (2004) 27-35
21. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160 (2003) 13-23
22. Kapur S., and Lecrubier Y. Dopamine in the Pathophysiology and Treatment of Schizophrenia-New Findings (2003), Martin Dunitz-Taylor & Francis Group, London, United Kingdom
23. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 2 (1987) 261-276
24. Kay S.R., Opler L.A., and Lindenmayer J.P. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res. 23 1 (1988) 99-110
25. Kopin I.J., Bankiewicz K.S., and Harvey-White J. Assessment of brain dopamine metabolism from plasma HVA and MHPG during debrisoquin treatment: validation in monkeys treated with MPTP. Neuropsychopharmacology 1 2 (1988) 119-125
26. Kubicki M., Westin C., Nestor P.G., Wible C.G., Frumin M., Maier S.E., Kikinis R., Jolesz F.A., McCarley R.W., and Shenton M.E. Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study. Biol. Psychiatry 54 (2003) 1171-1180
27. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: Implications from recent brain imaging studies. Brain Res. Rev. 31 (2000) 371-384
28. Laruelle M., and Abi-Dargham A. Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 13 (1999) 358-371
29. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S.E., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., and Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 62 (2005) 361-370
30. Lukoff D., Nuechterlein K.H., and Ventura J. Manual for the Expanded Brief Psychiatric Rating Scale. Schizophr. Bull. 12 (1986) 594-602
31. Marcelis M., Myin-Germeys I., Suckling J., Woodruff P., Hofman P., Bullmore E., Delespaul Ph., and Van Os J. Cerebral tissue alterations and daily life experience in psychosis. Acta Psychiatr. Scand. 107 (2003) 54-59
32. Marcelis M., Suckling J., Woodruff P., Hofman P., Bullmore E., and Van Os J. Searching for a structural endophenotype in psychosis using computational morphometry. Psychiatry Res. Neuroimaging 122 (2003) 153-167
33. Marcelis M., Cavalier E., Gielen J., Delespaul Ph., and Van Os J. Abnormal response to metabolic stress in schizophrenia: marker of vulnerability or acquired sensitization?. Psychol. Med. 34 6 (2004) 1103-1111
34. McGuffin P., Farmer A., and Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system [news]. Arch. Gen. Psychiatry 48 8 (1991) 764-770
35. Mitropoulou V., Goodman M., Sevy S., Elman I., New A.S., Iskander E.G., Silverman J.M., Breier A., and Siever L.J. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizotypal personality disorder. Schizophr. Res. 70 1 (2004) 27-31
36. Overall J.E., and Gorham D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 10 (1962) 779-812
37. Smeets R., and Dingemans P. Composite International Diagnostic Interview (CIDI) (1993), World Health Organization
38. Spitzer R.L., Endicott J., and Robbins E. Research Diagnostic Criteria (RDC) for a Selected Group of Functional Psychoses (1978), Biometrics Research Division, New York State Psychiatric Institute, New York
39. StataCorp, 2001. STATA Statistical Software: Release 8.0. College Station, Texas.
40. Suckling J., Brammer M.J., Lingford-Hughes A., and Bullmore E.T. Removal of extracerebral tissues in dual-echo magnetic resonance images via linear scale-space features. Magn. Reson. Imaging 17 (1999) 247-256
41. Suckling J., Sigmundsson T., Greenwood K., and Bullmore E.T. A modified fuzzy clustering algorithm for operator independent brain tissue classification of dual echo MR images. Magn. Reson. Imaging 17 (1999) 1065-1076
42. Vermetten E., and Bremner J.D. Circuits and systems in stress: I. Preclinical studies. Depress. Anxiety 15 (2002) 126-147
43. Weinberger D.R., and Lipka B.K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr. Res. 16 (1995) 87-110
44. WHO. WHO Coordinated Multicenter Study on the Course and Outcome of Schizophrenia (1992), World Health Organisation, Geneva
45. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., and Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 157 1 (2000) 16-25
46. Zhou S., Suzuki M., Hagino H., Takahashi T., Kawasaki Y., Nohara S., Seto Y., and Kurachi H. Decreased volume and increased asymmetry of the anterior limb of the internal capsule in patients with schizophrenia. Biol. Psychiatry 54 (2003) 427-436